India Globalization Capital, Inc. (NYSE: IGC) Targets Multiple Health Concerns with Cannabis-based Therapies
6 patents filed for pain management, eating disorders and epilepsy Additional patents underway for PTSD, depression, Alzheimer’s and Parkinson’s disease Revenue potential of each cannabis-based therapy could fetch between $100 million to $500 million India Globalization Capital (NYSE AMERICAN: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of Alzheimer’s, cachexia, pain, and other life-altering conditions. The company’s most recent research and development focus continues to be on readying a line of cannabis-based products targeting Alzheimer’s disease utilizing novel data (http://nnw.fm/l2NJw). This cannabis-based combination therapy shows promise for Alzheimer’s sufferers, says…